PARSEQ LAB (PARSEQ LAB CO. LTD.)

Company Snapshot

Founded: 2011
Entity Type: Private
Region: Russia
Headquarter: Moscow, Russia
Key Geographics: Russia
Corporate Address: st. Dolgorukovskaya, 27с1 127006, Moscow, Russia Tel: +7-499-550-6889 www.parseq.pro

Company Overview

Parseq Lab Co. Ltd., formerly known as Sequoia Genetics, is developing and commercializing diagnostics based on NGS platforms. Parseq Lab provides molecular genetics laboratories with a broad range of NGS solutions. The company’s ready-to-use kits analyze genetic variants in fields ranging from research to diagnostics.

The company’s main focus is on newborn screening, reproductive genetics, inherited disorders and registry typing (HLA typing NGS assays for bone marrow donor registries).

For newborn screening, Parseq markets its VariFind test, which is an NGS-based test that screens for cystic fibrosis, galactosemia and phenylketonuria in newborns that have a positive biochemical test.

The test is used on newborns that initially test with a value of 50 ng/mL or higher of immunoreactive trypsinogen (IRT). Normally, babies that test at a 70 ng/mL IRT level or higher go on to the second round of testing.

VariFind is run on the Ion Torrent PGM platform. The test sequences the CFTR, GALT and PAH genes and identifies up to 590 mutations in the CFTR gene, 43 mutations in the GALT gene and 107 mutations in the PAH gene.

For human identification, Parseq markets VariFind HID, which is designed to analyze samples that contain a small amount of DNA, have strongly degraded DNA, or contain mixtures of DNA from various sources. The test can be used for human identification, prediction of phenotypic traits or ancestry purposes.

PARSEQ LAB (PARSEQ LAB CO. LTD.) In Reports

Global DNA Sequencing: Research, Applied and Clinical Markets

BCC Research Market Report for DNA Sequencing Industry. Global market for DNA sequencing technologies and their applications in research, applied and clinical segments.

Global DNA Read, Write and Edit Market

The global market for DNA read, write and edit applications should grow from $17.0 billion in 2019 to $43.1 billion by 2024 with a compound annual growth rate of 20.5% during the period of 2019-2024.

Liquid Biopsy with Emphasis on Cancer: Global Markets to 2023

Get an overview of the global markets for liquid biopsy technologies, applications, industry subsegments along with analyses of global market trends with data from 2017, 2018 and projections of CAGRs through 2023 ...

PARSEQ LAB (PARSEQ LAB CO. LTD.) In News

Paragon snaps up Parseq - Printweek

Printweek - Feb 04, 2026

Company's Business Segments

  • Product : VariFind, PARallele, OncoScope, PureCode, Prep&Seq, Others
  • Services : Bioinformatics Tools and Services, Others

Applications/End User Industries

  • Healthcare
  • Pharmaceuticals
  • Medical Diagnostics
  • Research and Academics
  • Biotechnology
  • Oncology
  • Life Science
  • Genomics
AI Sentiment